Teratogenic potential of tribenoside, a drug for the treatment of haemorrhoids and varicose veins-A population-based case-control study

Tamás Kubicsek, Zoltan Kazy, E. Czeizel

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Tribenoside is used for the treatment of haemorrhoids and varicose veins, frequently in pregnant women as well, but published data regarding its possible teratogenic effect are not available. Thus the risk of congenital abnormalities (CAs) was estimated in cases of pregnant women with oral tribenoside treatment (TT) in the Hungarian Case-Control Surveillance System of Congenital Abnormalities. Of 22,843 cases with CA, 174 (0.76%), while of 38,151 matched controls without CA, 285 (0.75%) were born to mothers with TT. There was no higher risk for total CAs after TT during any time of pregnancy but congenital hydrocephaly had a higher risk after medically recorded TT in the second and/or third month of pregnancy, i.e. critical period of this CA. In conclusion TT in pregnant women associated with a higher risk of congenital hydrocephalus in their children, however, this finding is based on only 4 cases therefore requires further confirmation in future studies.

Original languageEnglish
Pages (from-to)464-469
Number of pages6
JournalReproductive Toxicology
Volume31
Issue number4
DOIs
Publication statusPublished - May 2011

Fingerprint

Hemorrhoids
Varicose Veins
Case-Control Studies
Pharmaceutical Preparations
Population
Pregnant Women
Hydrocephalus
Therapeutics
Pregnancy
tribenoside
Mothers

Keywords

  • Birth defects
  • Congenital hydrocephalus
  • Population-based case-control study
  • Pregnancy
  • Tribenoside

ASJC Scopus subject areas

  • Toxicology

Cite this

Teratogenic potential of tribenoside, a drug for the treatment of haemorrhoids and varicose veins-A population-based case-control study. / Kubicsek, Tamás; Kazy, Zoltan; Czeizel, E.

In: Reproductive Toxicology, Vol. 31, No. 4, 05.2011, p. 464-469.

Research output: Contribution to journalArticle

@article{6aa13ff9681b4760a72c818c62f2fe21,
title = "Teratogenic potential of tribenoside, a drug for the treatment of haemorrhoids and varicose veins-A population-based case-control study",
abstract = "Tribenoside is used for the treatment of haemorrhoids and varicose veins, frequently in pregnant women as well, but published data regarding its possible teratogenic effect are not available. Thus the risk of congenital abnormalities (CAs) was estimated in cases of pregnant women with oral tribenoside treatment (TT) in the Hungarian Case-Control Surveillance System of Congenital Abnormalities. Of 22,843 cases with CA, 174 (0.76{\%}), while of 38,151 matched controls without CA, 285 (0.75{\%}) were born to mothers with TT. There was no higher risk for total CAs after TT during any time of pregnancy but congenital hydrocephaly had a higher risk after medically recorded TT in the second and/or third month of pregnancy, i.e. critical period of this CA. In conclusion TT in pregnant women associated with a higher risk of congenital hydrocephalus in their children, however, this finding is based on only 4 cases therefore requires further confirmation in future studies.",
keywords = "Birth defects, Congenital hydrocephalus, Population-based case-control study, Pregnancy, Tribenoside",
author = "Tam{\'a}s Kubicsek and Zoltan Kazy and E. Czeizel",
year = "2011",
month = "5",
doi = "10.1016/j.reprotox.2010.12.001",
language = "English",
volume = "31",
pages = "464--469",
journal = "Reproductigve Toxicoloy",
issn = "0890-6238",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Teratogenic potential of tribenoside, a drug for the treatment of haemorrhoids and varicose veins-A population-based case-control study

AU - Kubicsek, Tamás

AU - Kazy, Zoltan

AU - Czeizel, E.

PY - 2011/5

Y1 - 2011/5

N2 - Tribenoside is used for the treatment of haemorrhoids and varicose veins, frequently in pregnant women as well, but published data regarding its possible teratogenic effect are not available. Thus the risk of congenital abnormalities (CAs) was estimated in cases of pregnant women with oral tribenoside treatment (TT) in the Hungarian Case-Control Surveillance System of Congenital Abnormalities. Of 22,843 cases with CA, 174 (0.76%), while of 38,151 matched controls without CA, 285 (0.75%) were born to mothers with TT. There was no higher risk for total CAs after TT during any time of pregnancy but congenital hydrocephaly had a higher risk after medically recorded TT in the second and/or third month of pregnancy, i.e. critical period of this CA. In conclusion TT in pregnant women associated with a higher risk of congenital hydrocephalus in their children, however, this finding is based on only 4 cases therefore requires further confirmation in future studies.

AB - Tribenoside is used for the treatment of haemorrhoids and varicose veins, frequently in pregnant women as well, but published data regarding its possible teratogenic effect are not available. Thus the risk of congenital abnormalities (CAs) was estimated in cases of pregnant women with oral tribenoside treatment (TT) in the Hungarian Case-Control Surveillance System of Congenital Abnormalities. Of 22,843 cases with CA, 174 (0.76%), while of 38,151 matched controls without CA, 285 (0.75%) were born to mothers with TT. There was no higher risk for total CAs after TT during any time of pregnancy but congenital hydrocephaly had a higher risk after medically recorded TT in the second and/or third month of pregnancy, i.e. critical period of this CA. In conclusion TT in pregnant women associated with a higher risk of congenital hydrocephalus in their children, however, this finding is based on only 4 cases therefore requires further confirmation in future studies.

KW - Birth defects

KW - Congenital hydrocephalus

KW - Population-based case-control study

KW - Pregnancy

KW - Tribenoside

UR - http://www.scopus.com/inward/record.url?scp=79956373731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956373731&partnerID=8YFLogxK

U2 - 10.1016/j.reprotox.2010.12.001

DO - 10.1016/j.reprotox.2010.12.001

M3 - Article

C2 - 21182931

AN - SCOPUS:79956373731

VL - 31

SP - 464

EP - 469

JO - Reproductigve Toxicoloy

JF - Reproductigve Toxicoloy

SN - 0890-6238

IS - 4

ER -